Lakefront Biotherapeutics NV GLPGF
35.15 USD 0.00 (+0.00%)
Regular-session close
35.15 Day range 35.15
26.24 52-week range 35.15
- YTD
- +12.34%
- 1 year
- +5.08%
Included in Essentials and up
Sign in to see Fair value
Discounted cash flow estimates against the price, and the P/E against its industry and sector.
Included in Essentials and up
Sign in to see Head count and owner earnings
Employees by annual report and the cash the business earns for its owners.
Included in Essentials and up
Sign in to see P/E against peers
The price to earnings ratio beside the closest competitors and their median.
Included in Essentials and up
Sign in to see Cash flow and returns
How profit turns into free cash flow, and the returns on equity, assets and capital.
Financial health
Altman Z-Score
21.95 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
A4 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 4
- P/E 3
- P/B 5
Valuation
P/E 5.5×
P/S 1.6×
P/B 0.5×
P/FCF -8.3×
EV/EBITDA 3.2×
EV/Sales 1.5×
FCF Yield -12.0%
Profitability
Gross Margin 97.3%
Operating Margin 42.2%
Net Margin 28.9%
ROE 9.9%
ROIC 14.4%
ROA 9.4%
Growth (YoY)
Revenue 303.4%
Operating Income 349.3%
EPS (diluted) 334.8%
Free Cash Flow 47.6%
Financial Health
Current Ratio 20.1×
Quick Ratio 20.0×
Debt / Equity 0.0×
Net Debt / EBITDA -0.2×
Interest Coverage 212×
Dividends
Dividend Yield 0.0%
Payout Ratio 0.0%
Annual · latest fiscal year ends 2025-12-31
